topotecan

P3, N=384, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

P2/3, N=108, Not yet recruiting, Incyte Corp.

P2, N=153, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed

P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: May 2026 --> Jul 2026

P3, N=722, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Jul 2026 --> Dec 2026

Moreover, drug sensitivity analysis indicated that the low-risk group was more responsive to olaparib, whereas the high-risk group showed increased sensitivity to Topotecan. Critically, functional experiments demonstrated that CERK knockout in this model significantly suppressed proliferation, migration, and invasion capacities in SKOV3 and ES-2 cell lines. We developed a sphingolipid metabolism-related prognostic signature (SRPS), which demonstrated robust performance in predicting survival outcomes and guiding personalized therapeutic strategies.

P2, N=120, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2026 --> Mar 2027

P3, N=398, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting

The patient was treated on a non-protocol treatment plan with five cycles of vincristine, carboplatin, etoposide, cyclophosphamide, and weekly intraventricular topotecan via Ommaya reservoir, followed by autologous stem cell rescue. Optical genome mapping (OGM) showed that the proximal breakpoint of the balanced inversion at 13q14.2 was within intron 17 of RB1, while the distal breakpoint at 13q31.3 did not interrupt any known genes of clinical significance. We review the various molecular techniques that aided in diagnosis of this patient and provide a summary of similar RB1-disrupting structural variants reported in the literature.

Drug likeness analysis results revealed that chalcone derivatives CD5, CD8, and CD9 and reference standard drugs lorlatinib and topotecan showed no violations against all five drug likeness rules. Current study overcomes these challenges by employing green nanocatalysts (Al(OH)₃ and Ti/Fe@Al(OH)₃) for eco-friendly, high-yield synthesis and computational screening to design potent, multi-target lung cancer therapeutic chalcone compounds. The online version contains supplementary material available at 10.1007/s40203-026-00599-3.

P1, N=20, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2026 --> Jun 2031 | Trial primary completion date: Aug 2026 --> Mar 2031

Preclinical studies indicate that pharmacological inhibition of SUMOylation with agents like TAK-981, topotecan, or Paromomycin reduces tumor growth, reverses therapy resistance, and enhances radiosensitivity. Moreover, SUMO-related enzymes, such as UBA2, SENP1, and SUMO2/3, may serve as prognostic biomarkers. Understanding SUMOylation in GBM offers insights into tumor biology and identifies potential therapeutic targets to improve patient outcomes.